Physician profile
Christopher Wroten
NPI 1902919913
$58,588.93
in general payments reported to CMS, 2019-2025
26 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,188 · 2020: $8,692 · 2021: $3,294 · 2022: $6,975 · 2023: $2,397 · 2024: $19K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $33K · Food and Beverage: $3,712 · Travel and Lodging: $1,397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,331.25 |
| Food and Beverage | $3,712.36 |
| Travel and Lodging | $1,396.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $39,193.53 | 2019-2025 | Dailies Total1, Precision 1, Total30 |
| Alcon Research LLC | $12,137.50 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $2,561.25 | 2020-2023 | |
| Allergan, INC. | $718.41 | 2019-2022 | |
| Abbvie INC. | $627.36 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $465.35 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $406.42 | 2021-2025 | Photrexa Viscous and Photrexa, Radius |
| Sun Pharmaceutical Industries INC. | $341.30 | 2019-2025 | Cequa |
| Dompe US, INC. | $309.22 | 2024-2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $237.93 | 2019-2025 | Acuvue |
| Carl Zeiss Meditec USA, INC. | $205.08 | 2022-2023 | Clarus |
| Biotissue Holdings INC. | $204.12 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $143.31 | 2023-2025 | Acthar |
| Harrow Eye, LLC | $139.19 | 2024-2025 | Tobradex St, Natacyn, Verkazia |
| Astellas Pharma Global Development | $125.15 | 2024 | Izervay |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $119.89 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $118.98 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $98.64 | 2019-2021 | |
| Oyster Point Pharma, INC. | $97.23 | 2022-2025 | Tyrvaya |
| Shire North American Group INC | $94.31 | 2019 | |
| Coopervision INC. | $89.96 | 2024 | Myday Contact Lens |
| Bausch & Lomb Americas INC. | $51.18 | 2024-2025 | Miebo, Infuse, Vyzulta |
| Eyevance Pharmaceuticals LLC | $34.56 | 2021 | |
| Maculogix, INC. | $25.97 | 2019 | |
| Kala Pharmaceuticals, INC. | $23.69 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wroten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.